The ARIES-HM3 Randomized Clinical Trial assessed the safety and efficacy of excluding aspirin from the antithrombotic regimen in patients with advanced heart failure who have undergone implantation of a fully magnetically levitated left ventricular assist device (LVAD). The clinical trial found that excluding aspirin from the antithrombotic regimen in patients with a levitated left ventricular assist device was safe.
The ARIES-HM3 Randomized Clinical Trial assessed the safety and efficacy of excluding aspirin from the antithrombotic regimen in patients with advanced heart failure who have undergone implantation of a fully magnetically levitated left ventricular assist device (LVAD). The clinical trial found that excluding aspirin from the antithrombotic regimen in patients with a levitated left ventricular assist device was safe. The ARIES-HM3 Randomized Clinical Trial assessed the safety and efficacy of excluding aspirin from the antithrombotic regimen in patients with advanced heart failure who have undergone implantation of a fully magnetically levitated left ventricular assist device (LVAD). The clinical trial found that excluding aspirin from the antithrombotic regimen in patients with a levitated left ventricular assist device was safe.